About Cynvec

Cynvec, an early stage biotech company based in New York City, was created in 2004 through the spin out of exclusively licensed IP from New York University focusing on the utility of the sindbis oncolytic viral vector in the treatment of cancer. It is based on the work of Dr. Daniel Meruelo, Ph.D., the world's leading authority on the virus and professor at NYU. Cynvec's lead product, CYN 101, is in late preclinical and will be in it's first Phase I trial in oncology by early 2010.

Sindbis Virus